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ABSTRACT We have fractionated a yeast whole cell
extract that can accurately splice synthetic actin and CYH2
pre-mRNAs. Three fractions, designated I, H, and m, have
been separated by use of ammonium sulfate fractionation and
chromatography on heparin agarose. Each fraction alone has
no splicing activity. Fractions I and H allow the rst step of the
splicing reaction to proceed, giving rise to the splicing inter-
mediates, free exon 1, and intron-exon 2. Addition of fraction
m completes the reaction. Micrococcal nuclease treatment of
the whole cell extract or of either fraction I or H abolished
splicing activity, indicating that fractions I and H have RNA
moieties that are required in the splicing reaction. The nature
ofthe RNAs was examined using antibodies directed against the
trimethylated cap structure unique to small nuclear RNAs.
Preincubation of the whole cell extract with protein A-Seph-
arose coupled to trimethylated cap antibody abolished splicing
activity. This indicates that at least one essential RNA compo-
nent contains a trimethyl cap. Thus, in yeast as in mammalian
systems, small nuclear RNAs are involved in mRNA splicing.
The recent development of in vitro splicing systems has
facilitated understanding of the mechanism of pre-mRNA
splicing (1-7). Characterization of the spliced products and
intermediates has led to a two-step model for mRNA splicing
(8, 9). The first step involves cleavage at the 5' splice site and
the formation of a lariat structure in which the 5' end of the
intervening sequence (IVS) isjoined in a 2'-5' phosphodiester
linkage to a specific residue a short distance upstream from
the 3' splice site (reaction 1). In the second step, the 3' splice
site is cleaved, and the two exons are joined (reaction 2).
Analysis of mutant pre-mRNAs with specific intron muta-
tions supports such a model (10, U. Vijayraghaven, R.
Parker, J. Rossi, J. Tamm, Y. limuva, J. A. & C. Guthrie,
unpublished work). Little further is known about the mech-
anism ofmRNA splicing. ATP is required for the reaction to
proceed (5-7), but its exact role has not been determined.
In mammalian systems some small nuclear ribonucleopro-
teins (snRNPs) are essential components of the splicing
machinery (11-17). The U1 snRNP has been implicated in the
recognition of the 5' splice junction and the U2 snRNP with
the site for branch formation near the 3' splice junction (14).
Since snRNPs contain an RNA molecule and at least S or 6
proteins (18), it could be anticipated that the mRNA splicing
machine would be large and complex. Evidence that this is so
has come from the discovery that the splicing intermediates
are found on a large particle (40S in yeast) termed the
"spliceosome" (19-21). The constituents of the spliceosome
are as yet unknown.
To understand the precise mechanism of mRNA splicing,
it will be necessary to identify the components involved in the
splicing reaction. We have undertaken fractionation of a
yeast whole cell extract and have separated three fractions
essential for mRNA splicing. We also show that a small
nuclear RNA (snRNA) is associated with at least one of the
components and is required for splicing.
MATERIALS AND METHODS
Materials. Bacteriophage SP6 RNA polymerase and
micrococcal nuclease were obtained from Boehringer-Mann-
heim. Protein A-Sepharose was from Pharmacia Fine Chem-
icals. Anti-trimethyl cap [(m3G)cap] antibody was a generous
gift of Joan Steitz (Yale University, New Haven, CT) and
also Reinhard Luhrmann (Max-Planck Institute of Molecular
Genetics, Berlin).
Fractionation of Yeast Whole Cell Extract. The following
(NH4)2SO4 fractionation procedure was for a 1-liter yeast
culture (2-3 x 107 cells/ml), and the percentage of(NH4)2SO4
represents percentage saturation at 250C. All (NH4)2SO4
precipitations were performed at 0C with stirring for 30 min
followed by centrifugation at 40C in a Sorvall SS-34 rotor at
17,000 rpm for 20 min. The yeast whole cell extract was
prepared according to Newman et al. (10). Solid (NH4)2SO4
was added to the supernatant from the 100,000 x g centrif-
ugation to yield a 70o saturated solution. The precipitate was
collected by centrifugation and resuspended in 10 ml of 40%6
saturated (NH4)2SO4, prepared by dissolving 24.2 g of solid
(NH4)2SO4 in 100 ml of 20 mM Hepes (pH 7.9), 0.2 mM
EDTA, and 0.5 mM dithiothreitol. After centrifugation, the
soluble fraction (40W) was concentrated by precipitation
with 70%o saturated (NH4)2SO4, and the pellet was dissolved
in 4 ml of 20 mM Hepes (pH 7.9), 0.2 mM EDTA, 0.5 mM
dithiothreitol, 50mM KCl, 20% (vol/vol) glycerol (buffer D).
The 40%6 saturated (NH4)2SO4 insoluble fraction (40P1) was
extracted twice more with 10 ml of40% saturated (NH4)2SO4.
The final pellet (40P3) was then dissolved in 0.15 ml of buffer
D. All fractions were then dialyzed for 3-4 hr against two
changes of 1 liter of bufferD followed by centrifugation in an
Eppendorf microfuge for 10 min to remove small amounts of
insoluble material and then stored at -70'C in aliquots.
Fraction 40W (20 mg) was diluted by a factor of 8 with 20
mM Hepes (pH 7.9), 0.5 mM EDTA, 0.5 mM dithiothreitol,
10% (vol/vol) glycerol (buffer I) and then applied to a 1-ml
heparin-agarose column preequilibrated with 0.05 M NaCl in
buffer I. After collection of the flow through fraction (0.05
M), the column was washed with 3-5 column volumes of0.05
M NaCl in buffer I. The column was then eluted successively
with 0.25 M and 0.5 M NaCl in buffer I. Fractions in 0.05 M
and 0.5 M NaCl were then stored at -70'C in aliquots.
Splicing Assay. Splicing assays were according to Newman
et al. (10) using uncapped actin pre-mRNA as substrate. In
those assays containing several fractions, each fraction
constituted 20% of the total reaction volume.
Abbreviations: IVS, intervening sequence(s); snRNP, small nuclear
ribonucleoprotein; snRNA, small nuclear RNA; trimethyl cap,
(m3G) cap.
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Micrococcal Nuclease Reactions. Micrococcal nuclease di-
gestions were carried out in a reaction mixture containing 2
mM CaCi2, 8 units of micrococcal nuclease, and 10 jud of
whole cell extract in a total volume of 18 ul. Reactions were
incubated at 30'C for 45 min and stopped by adding 0.8 ILI of
50 mM EGTA. To 14 Al of this reaction mixture was added
6 Al of the splicing reaction mix (10) and 5 A.l of the
complementation fraction or buffer D to assay splicing
activity.
Immunoprecipitation. Antiserum or preimmune serum was
coupled to protein A-Sepharose by incubation of 2 Al of
serum (20 mg/ml) with 0.5 mg of protein A-Sepharose at
room temperature for 1 hr in a total volume of 0.1 ml
containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, and
0.05% Nonidet P-40. The material was then washed three
times with 0.2 ml of the same buffer and twice with 0.2 ml of
buffer without Nonidet P-40. For depletion assays, 25 dul of
whole cell extract diluted 1:3 was incubated with the anti-
body-coupled protein A-Sepharose at 40C for 1 hr. After
removing protein A-Sepharose by centrifugation in a
microfuge for 5 sec, the supernatant was assayed for splicing
activity. For analysis of spliced RNA bound to antibody,
splicing reactions were carried out at 23°C for 10 min in a total
volume of 25 Al containing 5 ,ul each of fractions 40P3 and
40W. Reactions were then added to the antibody-coupled
protein A-Sepharose on ice followed by incubation at 4°C for
1 hr. After removing the supernatant, the protein A-Seph-
arose was washed four times with 25 ,ul of 50 mM Tris HCl
(pH 7.4), 150 mM NaCl at 4°C and then subjected to
phenol/chloroform extraction and ethanol precipitation fol-
lowed by RNA analysis (10).
RESULTS
Fravdionation of the Whole Cell Extract. The results of the
fractionation experiments are summarized in Fig. 1 and are
discussed in detail below. In summary, three fractions
required for pre-mRNA splicing have been separated by use
ofammonium sulfate fractionation and heparin-agarose chro-
matography. They are designated fractions I, II, and III. The
fractionation scheme is shown in Fig. 1A and the involvement
of these fractions in the splicing pathway in Fig. 1B. Each
fraction by itself does not contain any splicing activity. A
mixture of fractions I and II can carry out the first step of the
splicing reaction, and a combination of all three fractions
gives the complete reaction (Fig. 1B).
The whole cell extract was precipitated with 70% saturated
(NH4)2S04 followed by back extraction ofthe pellet with 40%
saturated (NH4)2SO4. The insoluble fraction 40P1 gave a
reaction in which the two splicing intermediates, free exon 1
and lariat intron-exon 2, accumulated (Fig. 2A). The reaction
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FIG. 1. (A) Scheme of fractionation of the mRNA splicing
extract. (B) The mRNA splicing pathway and the involvement of
fractions I, II, and III in the pathway.
in crude extract or 70P accumulated only small amounts of
the intermediates (Fig. 2A). This indicates that the 40P1
fraction is deficient in some component responsible for the
second step of the splicing reaction. Fraction 40W, which
alone did not show any activity (Fig. 2A), when added to
40P1, restored complete splicing activity without accumula-
tion of intermediates (Fig. 2A). To completely eliminate
reaction 2 activity from 40P1, the fraction was extracted
twice with 40% saturated (NH4)2SO4, yielding the insoluble
fraction 40P3. The 40P3 fraction did not have any splicing
activity on its own (Fig. 2A). However, addition of 40W to
40P3 restored full activity (Fig. 2A), indicating both 40P3 and
40W were essential for splicing although each alone showed
no activity. The fact that both reaction 1 and 2 activities in
fraction 40P1 could be removed by two more 40% saturated
(NH4)2SO4 washings indicated that in the 40P1 fraction, only
a small amount of some components required for reaction 1
and 2 remained. The accumulation of splicing intermediates
in the 40P1 reaction suggests that the reaction 2 activity was
more depleted than reaction 1 activity in the 40P1 fraction.
This also indicated the two activities were conferred by at
least two distinct components, the majority of which were
present in the 40W fraction. We, therefore, named 40P3
fraction I and fractionated further the 40W fraction.
Heparin-agarose chromatography separated fraction 40W
into two fractions (Fig. 2B). The flow through fraction (0.05
M NaCl) gave mainly reaction 1 when assayed in the presence
of fraction I (lane 3), and was named fraction II. Addition of
the fraction eluted from heparin-agarose column between
0.25M and 0.5M NaCl (fraction III) also gave reaction 2 (lane
6). As shown in Fig. 2B, the 0.5 M NaCl eluate gave a small
amount of activity without accumulation of intermediates
when fraction I but not fraction II was included in the assay
(lane 5). When the flow through fraction (fraction II) was also
added, it showed much higher activity (lane 6). Fraction III,
therefore, contained small amounts of the activity required
for reaction 1, allowing reaction 2 to proceed. On the other
hand, fraction II also contained a small amount of reaction 2
activity (lane 3). It is possible that there is an affinity between
essential components in fraction II plus III. As a conse-
quence, the activities characteristic of fraction II plus III
cannot be totally separated.
Involvement of RNA Components. In mammalian systems,
snRNP are required for mRNA splicing (11-13, 15-17, 22).
Although in yeast snRNPs have not been identified as such,
snRNAs have been shown to exist by Wise et al. (23). To
examine whether an RNA component is involved in yeast
mRNA splicing, we first tested the sensitivity of the splicing
extract to micrococcal nuclease treatment. Pretreatment of
the whole cell extract with micrococcal nuclease in the
presence of CaCl2 abolished all the splicing activity (Fig. 3).
In a control, preincubation was carried out in the presence of
EGTA as well as CaCl2, and the extract remained active.
Thus loss of activity after micrococcal nuclease treatment
was not due to an inhibitor present in the micrococcal
nuclease fraction or incomplete inactivation of micrococcal
nuclease by EGTA. Since splicing activity was not affected
by pancreatic deoxyribonuclease at 10 jig/ml (76 units/,ug of
DNase I, Calbiochem), we conclude that the whole cell
extract contains someRNA component essential for splicing.
To determine which of the three fractions contains RNA,
they were added to a micrococcal nuclease-treated extract to
test for complementation (Fig. 3). Addition offraction I alone
or II plus III (40W) did not restore splicing activity, while
addition of fractions I and II restored full activity. This
indicated that both fractions I and II contain sensitive RNA
moieties that were inactivated after micrococcal nuclease
treatment, whereas fraction III was not. It is possible that
fractions I and II contain components tightly associated in the
whole cell extract, so that even though only one fraction was
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inactivated, both fractions had to be added to restore activity.
Thus it was necessary to test the micrococcal nuclease
sensitivity with separated fractions I and II. Pretreatment of
fraction I or II plus III (40W) with micrococcal nuclease
abolished ability of each to yield spliced RNA or intermedi-
ates (data not shown). The activity could be restored by
addition of the missing fraction. This suggests that both
fractions I and II contain a micrococcal nuclease sensitive
component, most likely an RNA molecule.
Depletion of Components Required for Splicing by Anti-
(m3G)cap Antiserum. It has been demonstrated that antibod-
ies directed against U1 snRNP inhibit pre-mRNA splicing in
a mammalian cell free system (11, 15). One of the features of
the U-class of snRNAs is the presence of a distinctive cap, a
trimethylated guanosine residue linked to the 5'-encoded
residue by a 5'-5' triphosphate bridge. Antibodies directed
against the (m3G)cap inhibit splicing in the mammalian
system (12). Guthrie et al. (24) have shown that the anti-
(m3G)cap antibody prepared by Chabot et al. (25) precipitates
yeast small nuclear RNAs. These RNAs were shown to
contain a mixture of dimethyl and trimethyl guanosine caps
(23). Since both fractions I and II appeared to contain RNA
moieties, it was possible that they were snRNAs. To inves-
tigate the possible involvement of snRNA in pre-mRNA
splicing in yeast, we performed "depletion experiments"
using anti-(m3G)cap antibody (12). Preincubation of the
whole cell extract with anti-(m3G)cap antibody coupled to
protein A-Sepharose followed by removal of the protein
A-Sepharose precipitate resulted in a 80-90% loss of splicing
FIG. 2. Splicing assays of the
fractions. (A) Ammonium sul-
fate fractionation of the whole
cell extract. Each assay shows
5-min, 10-min, and 20-min reac-
tions. CE, crude extract; 70P,
70% saturated (NH4)2SO4 pre-
cipitate; 40P1, precipitate of 70P
extracted with 40% saturated
(NH4)2SO4 once; 40W, superna-
tant of 70P extracted with 40%6
saturated (NH4)2SO4; 40P3, pre-
cipitate of 70P extracted with
40%o saturated (NH4)2SO4 three
times. (B) Heparn-agarose chro-
matography of 40W fraction.
Lane 1: fraction I alone. Lanes
2-6 fraction I was added to the
following: lane 2, 40W fraction
diluted 1:8; lane 3, 0.05 M NaCl
eluate; lane 4, 0.25 M NaCl elu-
ate; lane 5, 0.5 M NaCl eluate;
lane 6, 0.05 M NaCl eluate plus
0.5 M NaCl eluate. IVS E2,
intron-exon 2; IVS, intron; p,
precursor; m, message; El,
exon 1.
activity (Fig. 4). Preincubation with the pre-immune serum
did not show any significant effect. This suggests that in the
whole cell extract, some component required for splicing
reacted with the antibody and was removed from the-extract
after precipitation. To determine which traction contains
snRNAs, we performed experiments with fraction I and-.40W
(fraction II plus III). As in the whole cell extract, fraction I
lost its splicing activity after preincubation with the antbody
(data not shown), presumably due to depletion of snRNA
from the fraction. Fraction 1I plus III (40W) showed no effect
despite the fact that fraction II apparently contains-an RNA
moiety by the criteria of micrococcal nuclease sensitivity.
A Splicing Complex Associated with snRNA. As demon-
strated by Black et al. (13), in mammalian systems both U1
and U2 snRNPs interact with the pre-mRNA during the
splicing reaction. The complexes ofpre-mRNAand Ul or U2
snRNP can be immunoprecipitated by antibodies directed
against U1 or U2 snRNPs. Although snRNPs have not been
characterized in yeast, it is likely that they exist since yeast
has snRNAs. Anti-(m3G)cap antibody was used to investi-
gate a possible specific interaction between the snRNA and
pre-mRNA and spliced products. Fig. 5A shows the exper-
imental procedure. A splicing reaction mixture containing
labeled pre-mRNA was incubated for 10 min and then added
to protein A-Sepharose-coupled anti-(m3G)cap antibody. Af-
ter removal of the unreacted material, RNA species bound to
the antibody were recovered and analyzed by gel electro-
phoresis. As shown in Fig. SB, approximately 20% of the
pre-mRNA was immunoprecipitated from the splicing reac-
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FIG. 3. Splicing assays of micrococcal nuclease (MN)-treated
whole cell extracts. Each assay shows 10-min and 20-min reaction
points. -MN, extract not treated with MN; EGTA-*MN, extract
treated with MN in the presence of EGTA; +MN, extracts pretreat-
ed with MN and complemented with fractions indicated.
tion. The same percentage of the excised exon 1, lariat
intron-exon 2, and IVS were also precipitated but only about
2% of mature message was precipitated. Formation of com-
plexes specific to the mRNA splicing reaction has been
shown by sedimentation analysis on glycerol or sucrose
gradient in both yeast and mammalian systems (19-21). This
complex, the spliceosome, contains pre-mRNA, exon 1,
lariat IVS, and lariat IVS-exon 2. The spliced mRNA,
however, is not found in the complex. Immunoprecipitation
by anti-(m3G)cap antibody of the same RNA species as found
in the spliceosome suggests that the precipitate contained the
complex or a related complex. These results suggest that a
(m3G)-capped snRNA, possibly as snRNP, forms part of the
active complex.
DISCUSSION
By use of ammonium sulfate fractionation and heparin-
agarose chromatography, we have identified three fractions
required for yeast mRNA splicing. Each fraction alone does
not show any splicing activity. Combination offractions I and
II allowed reaction 1 to proceed. Addition of fraction III
allowed completion of the splicing reaction. Both fractions I
and II are sensitive to micrococcal nuclease and so are likely
to contain essential RNA moieties. The RNA in fraction I
contains RNA with a cap structure since it can be depleted by
preincubation with protein A-Sepharose-coupled anti-
(m3G)cap antibody. The possession of a (m3G)cap by the
RNA(s) in fraction I suggests that this fraction contains an
snRNA (23). The fact that the pre-mRNA and splicing
intermediates found in the 40S complex are also im-
FIG. 4. Splicing assays of depleted whole cell extracts. Each
assay shows 10-min, 20-min, and 30-min reaction points. Extracts
were depleted with: PAS protein A-Sepharose; Pre-Immune, protein
A-Sepharose-coupled pre-immune serum; a-(m3G)cap, protein A-
Sepharose-coupled a-(m3G)cap antibody.
munoprecipitable by anti-(m3G)cap antibody suggests at least
one snRNA possibly in the form of a ribonucleoprotein
particle forms part of the 40S complex. In mammalian
systems, both U1 and U2 snRNPs have been shown to be
involved in pre-mRNA splicing (11-17). U1 snRNPs interact
with the 5' splice site (13, 26), and U2 snRNPs preferentially
interact with a region of the pre-mRNA that includes the
intron branch point (13). It is conceivable that in yeast
snRNPs also interact with pre-mRNA and play a role in
recognition of splicing signals.
Formation of the 40S complex requires that pre-mRNA
undergo at least the first step of splicing reaction (20).
Incubation ofpre-mRNA with fraction I alone did not give the
40S complex on a glycerol gradient (G. McFarland and J.A.,
unpublished results), nor did it show significant immuno-
precipitability by anti-(m3G)cap antibody (unpublished re-
sults). Evidently, a component in fraction II is required
together with components of fraction I for formation of the
splicing complex. Since fraction II is required for the first
step of the splicing reaction, it could be a multifunctional
complex responsible for both recognition of splicing signals
and catalytic cleavage ofthe 5' splice site and formation ofthe
lariat, or it could consist of several separable components
that mediate those steps. The latter is not unlikely since at
least six distinct factors necessary for pre-mRNA splicing in
vitro have been identified in the mammalian system (14, 27).
Alternatively, fraction II as well as fraction I may be required
only for formation of the splicing complex, organizing the
branch point and at least the 5' splice site of the pre-mRNA
into a proper configuration so that splicing can take place in
an autocatalytic fashion.
Fraction II contains a micrococcal nuclease-sensitive com-
ponent. The results of the depletion experiment, however,
showed that fraction II could not be inactivated by prein-
cubation with protein A-Sepharose-coupled anti-(m3G)cap
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FIG. 5. (A) Scheme of immunoprecipitation of splicing reactions.
(B) Splicing reactions. Pre-Immune, precipitated with protein A-
Sepharose-coupled pre-immune serum; a-(m3G)cap, precipitated
with protein A-Sepharose-coupled a-(m3G)cap antibody; Reac-
tion(1/5), 1/5 volume of reaction not precipitated.
antibody, indicating that the RNA associated with it could
not react with antibody. The nature of this RNA is not
known. It is possible that the RNA is capped but is in such
a configuration that it is not accessible to the antibody or that
it is a molecule similar to snRNA but is not capped at the 5'
end as in the case ofU6 snRNA (28, 29). One cannot exclude
the possibility that this RNA represents a distinct species
different from the U class snRNAs and plays a catalytic role
in the splicing reaction. Catalytic RNAs have been demon-
strated in ribonuclease P (30) and in self-splicing reactions
(31, 32).
The activities that mediate steps 1 and 2 seem to be
associated with each other as evidenced by their fractionation
behavior: (i) They cofractionated from 40%o to 70%o saturated
(NH4)2SO4 (data not shown). (ii) The activities could be
separated but never completely in several chromatographic
steps. The amount of reaction 2 activity associated with
fraction II diminished with increased dilution of the 40W
fraction loaded on the column (data not shown). This sug-
gested that reaction 2 activity dissociated from reaction 1
activity upon dilution ofthe 40W fraction and could then bind
to the column. However, a small amount ofreaction 2 activity
that was still associated with reaction 1 activity also bound.
We have not been able to completely separate the two
activities.
The fact that a splicing complex could be precipitated by
anti-(m3G)cap antibody indicated that the complex contained
a trimethylated cap accessible to the antibody. In the mam-
malian system, the 5'-terminal sequence of U1 snRNA has
been proposed to base pair with the sequence of the intron of
pre-mRNA at the 5' splice site (12). Although the same
phenomenon has not been demonstrated in yeast, by analogy
it is likely that some yeast snRNA plays a role similar to U1
in recognition of the 5' splice site. If this is the case, the
accessibility of the cap to the antibody would indicate the 5'
terminus of this U1 like snRNA is not folded inside the
complex and is still accessible to the antibody after pairing
with the pre-mRNA, or else there may be some other capped
snRNA in the complex providing the free cap for the
antibody. In collaboration with C. Guthrie, N. Riedel, and B.
Patterson (unpublished results), we have found that fraction
I is greatly enriched in several of the yeast snRNAs. Inves-
tigation of these RNAs by both genetic and biochemical
approaches should establish their role in the mRNA splicing
reaction.
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